Volume Alert - GILD 105.07 Gilead Sciences $GILD H
Post# of 145218
Posted On: 11/13/2014 11:03:13 AM
Volume Alert - GILD 105.07 Gilead Sciences $GILD Hit a high today of 107.05 Closing the day 10:30 at 105.07 -1.83 -1.71% With a day low of 104.42 and a total volume of 6,541,977.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 18 mins ago
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 105.07 (-1.83)
Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 105.07 (-1.83)
Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 105.09 (-1.81), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 105.09 (-1.81)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.49 (+0.98), JNJ: 109.37 (+0.62), GILD: 105.09 (-1.81), ABBV: 64.38 (+0.62)
Gilead Sciences Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.09 (-1.81)
Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.08 (-1.82)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62)
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST
GILD: 105.08 (-1.82), MRK: 59.89 (+0.58)
Should Investors Buy Twitter Following Its Analyst Day?
at The Street - Wed Nov 12, 2:08PM CST
The CNBC's 'Fast Money Halftime' trading panel says Twitter has a lot of potential but needs to find a way to grow its user base and engagement.
DHI: 24.39 (+0.38), FB: 74.60 (-0.12), WMT: 81.89 (+2.69), M: 60.96 (-0.61), BZH: 19.08 (+0.46), TLT: 118.62 (-0.01), DNKN: 48.94 (+0.85), SPY: 204.67 (+0.71), TJX: 63.71 (-0.02), EBAY: 54.46 (+0.40), QQQ: 103.22 (+0.76), GILD: 105.08 (-1.82), TGT: 67.61 (+0.89), DIA: 176.89 (+0.85), FL: 55.66 (-0.07), IWM: 117.99 (+0.09), TWTR: 42.71 (+0.17), TOL: 33.87 (+0.36), AAPL: 113.21 (+1.96)
Midday Glance: Biotechnology companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Searching The Stars For Quality Stocks
Brad Kenagy - at Seeking Alpha - Wed Nov 12, 10:43AM CST
PCAR: 66.98 (+0.08), GILD: 105.08 (-1.82), AMP: 130.42 (+0.14), CMCSA: 54.45 (+0.85)
Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - Wed Nov 12, 10:17AM CST
GILD: 105.08 (-1.82)
Early Glance: Biotechnology companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.42 (-0.26), GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), DNDN: 0.15 (-0.01), AMGN: 162.01 (+0.08), ABBV: 64.38 (+0.62), REGN: 399.91 (-1.20)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ
NDN), and Juniper (NYSE:JNPR).
GILD: 105.08 (-1.82), DNDN: 0.15 (-0.01), ZNGA: 2.84 (+0.03), AAPL: 113.20 (+1.95), JNPR: 20.66 (-0.21), BABA: 118.45 (+0.25)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), MRK: 59.89 (+0.58)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.99 (+0.18), SJR: 26.27 (+0.07), PRGO: 155.77 (+0.90), XYL: 37.42 (-0.13), CHRW: 72.88 (+0.02), MDLZ: 38.15 (+0.23), MKC: 73.46 (+0.23), MDU: 25.21 (-0.21), SYY: 38.88 (-0.06), PDCO: 45.73 (+0.60), PNR: 68.74 (+0.30), TRI: 38.20 (-0.04), UPS: 108.52 (-0.10), PEP: 98.62 (+1.46), AGN: 197.49 (+0.98), MSI: 64.36 (+0.66), NOV: 71.49 (-1.51), NWN: 47.04 (-0.05), EGN: 66.91 (-1.79), EBAY: 54.46 (+0.40), QCOM: 70.70 (+0.41), AMAT: 22.82 (+0.33), ACN: 84.55 (+0.43), AAPL: 113.20 (+1.95), MA: 84.27 (-0.08), SCHW: 28.81 (+0.03), STR: 23.84 (-0.10), SE: 38.26 (-0.70), GAS: 51.87 (-0.25), IRM: 38.09 (+0.04), WM: 49.38 (unch), CMP: 88.80 (+0.11), VRSK: 63.04 (-0.08), GILD: 105.08 (-1.82), EXPD: 43.87 (-0.04), TFX: 114.53 (+0.06), CVS: 90.03 (+0.74), PG: 89.76 (+0.28), PX: 126.61 (+0.38), NVS: 94.38 (+1.72)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.49 (+0.98), GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62), BMY: 58.03 (-0.58)
Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 105.08 (-1.82)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 18 mins ago
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 105.07 (-1.83)
Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 105.07 (-1.83)
Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 105.09 (-1.81), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 105.09 (-1.81)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.49 (+0.98), JNJ: 109.37 (+0.62), GILD: 105.09 (-1.81), ABBV: 64.38 (+0.62)
Gilead Sciences Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.09 (-1.81)
Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.08 (-1.82)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62)
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST
GILD: 105.08 (-1.82), MRK: 59.89 (+0.58)
Should Investors Buy Twitter Following Its Analyst Day?
at The Street - Wed Nov 12, 2:08PM CST
The CNBC's 'Fast Money Halftime' trading panel says Twitter has a lot of potential but needs to find a way to grow its user base and engagement.
DHI: 24.39 (+0.38), FB: 74.60 (-0.12), WMT: 81.89 (+2.69), M: 60.96 (-0.61), BZH: 19.08 (+0.46), TLT: 118.62 (-0.01), DNKN: 48.94 (+0.85), SPY: 204.67 (+0.71), TJX: 63.71 (-0.02), EBAY: 54.46 (+0.40), QQQ: 103.22 (+0.76), GILD: 105.08 (-1.82), TGT: 67.61 (+0.89), DIA: 176.89 (+0.85), FL: 55.66 (-0.07), IWM: 117.99 (+0.09), TWTR: 42.71 (+0.17), TOL: 33.87 (+0.36), AAPL: 113.21 (+1.96)
Midday Glance: Biotechnology companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Searching The Stars For Quality Stocks
Brad Kenagy - at Seeking Alpha - Wed Nov 12, 10:43AM CST
PCAR: 66.98 (+0.08), GILD: 105.08 (-1.82), AMP: 130.42 (+0.14), CMCSA: 54.45 (+0.85)
Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - Wed Nov 12, 10:17AM CST
GILD: 105.08 (-1.82)
Early Glance: Biotechnology companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.42 (-0.26), GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), DNDN: 0.15 (-0.01), AMGN: 162.01 (+0.08), ABBV: 64.38 (+0.62), REGN: 399.91 (-1.20)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ
NDN), and Juniper (NYSE:JNPR). GILD: 105.08 (-1.82), DNDN: 0.15 (-0.01), ZNGA: 2.84 (+0.03), AAPL: 113.20 (+1.95), JNPR: 20.66 (-0.21), BABA: 118.45 (+0.25)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), MRK: 59.89 (+0.58)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.99 (+0.18), SJR: 26.27 (+0.07), PRGO: 155.77 (+0.90), XYL: 37.42 (-0.13), CHRW: 72.88 (+0.02), MDLZ: 38.15 (+0.23), MKC: 73.46 (+0.23), MDU: 25.21 (-0.21), SYY: 38.88 (-0.06), PDCO: 45.73 (+0.60), PNR: 68.74 (+0.30), TRI: 38.20 (-0.04), UPS: 108.52 (-0.10), PEP: 98.62 (+1.46), AGN: 197.49 (+0.98), MSI: 64.36 (+0.66), NOV: 71.49 (-1.51), NWN: 47.04 (-0.05), EGN: 66.91 (-1.79), EBAY: 54.46 (+0.40), QCOM: 70.70 (+0.41), AMAT: 22.82 (+0.33), ACN: 84.55 (+0.43), AAPL: 113.20 (+1.95), MA: 84.27 (-0.08), SCHW: 28.81 (+0.03), STR: 23.84 (-0.10), SE: 38.26 (-0.70), GAS: 51.87 (-0.25), IRM: 38.09 (+0.04), WM: 49.38 (unch), CMP: 88.80 (+0.11), VRSK: 63.04 (-0.08), GILD: 105.08 (-1.82), EXPD: 43.87 (-0.04), TFX: 114.53 (+0.06), CVS: 90.03 (+0.74), PG: 89.76 (+0.28), PX: 126.61 (+0.38), NVS: 94.38 (+1.72)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.49 (+0.98), GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62), BMY: 58.03 (-0.58)
Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 105.08 (-1.82)
(0)
(0)